[Personal genomics: are we debating the right Issues?].
The debate about personal genomics and their role in personalized medicine has been, to some extent, hijacked by the controversy about commercially available genomic tests sold directly to consumers. The clinical validity and utility of such tests are currently limited and most medical associations recommend that consumers refrain from testing. Conversely, DTC genomics proponents and particularly the DTC industry argue that there is personal utility in acquiring genomic information. While it is necessary to debate risks and benefits of DTC genomics, we should not lose sight of the increasingly important role that genomics will play in medical practice and public health. Therefore, and in anticipation of this shift we also need to focus on important implications from the use of genomics information such as genetic discrimination, privacy protection and equitable access to health care. Undoubtedly, personal genomics will challenge our social norms maybe more than our medicine. Sticking to the polarization of «to have or not to have DTC genomics» risks to takes us away from the critical issues we need to be debating.
Institut für Biomedizinische Ethik, Universität Zürich. vayena@ethik.uzh.ch
E
E
Vayena
F
F
Mauch
D005544:Forecasting; D033141:Genetic Determinism; D030661:Genetic Privacy / Q000639:trends; D005820:Genetic Testing / Q000639:trends; D023281:Genomics / Q000639:trends*; D006801:Humans; D010358:Patient Participation; D057285:Precision Medicine / Q000639:trends*; D011933:Reagent Kits, Diagnostic / Q000639:trends; D015203:Reproducibility of Results; D013557:Switzerland
D011933:Reagent Kits, Diagnostic